Atara Biotherapeutics, Inc.
ATRAAtara Biotherapeutics, Inc. in brief
Atara Biotherapeutics, Inc. is a listed company in the Biotechnology industry, based in Thousand Oaks, California, USA. It was founded in 2012. Its market value was $96 M on 23 October 2026, which makes it the 18,848th largest listed company in the world and the 3,528th largest in the USA on this site. In the year to December 2025 it had sales of $121 M and a net profit of $33 M, about 27 cents of profit for every dollar of sales. It employs about 578 people and AnhCo Nguyen is its chief executive. Its shares trade under the symbol ATRA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics is a off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. It is estimated that the annual revenue is currently $36M per year and has 450 Employees as on 2019. The headquarters is in USA.
Atara Biotherapeutics, Inc. timeline
- 2012
- 🏁· approximateFounded
- 2014
- 🔔· approximateInitial public offering on Nasdaq
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2024
- 💰Record revenue of $129 millionFY2024, the highest of the 4 years on record.
Events of Atara Biotherapeutics, Inc. from Wikidata, the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,027 (Jan 2020) · #1,801 (Jan 2021) · #2,245 (Jan 2022) · #3,303 (Dec 2022) · #3,597 (Jul 2023) · #4,110 (Jan 2024) · #2,205 (Mar 2026) · #3,536 (Aug 2026) · #3,516 (Oct 2026) · #3,532 (Oct 2026)
Key ratios
- P/E ratio
- 2.9×
- Price / sales
- 0.8×
- Price / book
- —
- Free cash flow yield
- -53.0%
- Net margin
- 27.1%
- Operating margin
- 29.7%
- Return on equity
- —
- Liabilities / assets
- 290.2%
- Revenue growth
- -6.3%
- R&D / revenue
- 31.0%
- Revenue per employee
- $209 K
- Profit per employee
- $57 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $121M | -6.3% | $36M | $33M | 27.1% |
| Dec 2024 | $129M | +1404.6% | $-83M | $-85M | -66.2% |
| Dec 2023 | $9M | -86.5% | $-276M | $-276M | -3222.1% |
| Dec 2022 | $64M | — | $-281M | $-228M | -359.1% |
| Dec 2021 | — | — | $-340M | $-340M | — |
| Dec 2020 | — | — | $-309M | $-307M | — |
| Dec 2019 | — | — | $-296M | $-291M | — |
| Dec 2018 | — | — | $-237M | $-231M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-51M | $0M | $-51M | $2.57 | — |
| Dec 2024 | $-69M | $0M | $-69M | $-11.41 | — |
| Dec 2023 | $-193M | $1M | $-194M | $-65.19 | — |
| Dec 2022 | $-270M | $4M | $-275M | $-2.24 | — |
| Dec 2021 | $-221M | $11M | $-231M | $-3.63 | — |
| Dec 2020 | $-181M | $5M | $-185M | $-4.15 | — |
| Dec 2019 | $-236M | $6M | $-241M | $-5.67 | — |
| Dec 2018 | $-180M | $36M | $-216M | $-5.27 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (-64.6% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jun 26, 20268-KCurrent reportDirectors or officers changed
- Jun 12, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent report
- May 7, 20268-KCurrent reportOther events
- May 1, 20268-KCurrent reportListing notice
- Apr 24, 2026DEF 14AProxy statement
- Mar 16, 202610-KAnnual report · period to Dec 2025
Official filings of Atara Biotherapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $121 M
- Operating income
- $36 M
- Net income
- $33 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $20 M
- Total liabilities
- $59 M
- Total equity
- $-39 M
As of December-2025
Top 35 institutional investors in Atara Biotherapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 1,552,000 | 0 (0.00%) | 15.23% | $13 M | Nov 16, 2026 |
| 2 | Adage Capital Partners GP, L.L.C. | 850,000 | 0 (0.00%) | 8.34% | $7 M | Nov 16, 2026 |
| 3 | Point72 Asset Management, L.P. | 677,696 | -10,022 (-1.46%) | 6.65% | $6 M | Nov 16, 2026 |
| 4 | Redmile Group, LLC | 636,852 | +195,151 (+44.18%) | 6.25% | $5 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 247,047 | 0 (0.00%) | 2.42% | $2 M | Nov 13, 2026 |
| 6 | Mackenzie Financial Corp | 176,758 | -56,491 (-24.22%) | 1.73% | $2 M | Nov 2, 2026 |
| 7 | BlackRock, Inc. | 85,302 | +847 (+1.00%) | 0.84% | $1 M | Nov 13, 2026 |
| 8 | Geode Capital Management, LLC | 80,950 | +5,822 (+7.75%) | 0.79% | $1 M | Nov 6, 2026 |
| 9 | Vanguard Fiduciary Trust Co | 50,703 | +7,667 (+17.82%) | 0.50% | $0 M | Nov 13, 2026 |
| 10 | Staley Capital Advisers Inc | 50,000 | 0 (0.00%) | 0.49% | $0 M | Nov 6, 2026 |
| 11 | Citadel Advisors LLC | 43,079 | +32,920 (+324.05%) | 0.42% | $0 M | Nov 16, 2026 |
| 12 | State Street Corp | 26,453 | 0 (0.00%) | 0.26% | $0 M | Nov 12, 2026 |
| 13 | UBS Group AG | 20,756 | +16,777 (+421.64%) | 0.20% | $0 M | Nov 10, 2026 |
| 14 | Northern Trust Corp | 16,705 | +114 (+0.69%) | 0.16% | $0 M | Nov 16, 2026 |
| 15 | FMR LLC | 16,278 | +40 (+0.25%) | 0.16% | $0 M | Nov 10, 2026 |
| 16 | Bridgeway Capital Management, LLC | 13,760 | -240 (-1.71%) | 0.14% | $0 M | Nov 16, 2026 |
| 17 | Empowered Funds, LLC | 13,760 | New | 0.14% | $0 M | Nov 13, 2026 |
| 18 | Acadian Asset Management LLC | 11,538 | -27,307 (-70.30%) | 0.11% | $0 M | Nov 9, 2026 |
| 19 | Morgan Stanley | 9,176 | -2 (-0.02%) | 0.09% | $0 M | Nov 13, 2026 |
| 20 | Royal Bank Of Canada | 8,751 | +4,008 (+84.50%) | 0.09% | $0 M | Nov 16, 2026 |
| 21 | Employees Retirement System of Texas | 5,154 | New | 0.05% | $0 M | Nov 10, 2026 |
| 22 | Vanguard Global Advisers, LLC | 4,654 | +3,198 (+219.64%) | 0.05% | $0 M | Nov 13, 2026 |
| 23 | SBI Securities Co., Ltd. | 1,404 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 24 | Jones Financial Companies Lllp | 303 | -500 (-62.27%) | 0.00% | $0 M | Nov 13, 2026 |
| 25 | Caitong International Asset Management Co., Ltd | 266 | -45 (-14.47%) | 0.00% | $0 M | Oct 29, 2026 |
Show all 35: investors 26 to 35
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Wells Fargo & Company/mn | 251 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 27 | Jpmorgan Chase & Co | 222 | +6 (+2.78%) | 0.00% | $0 M | Nov 12, 2026 |
| 28 | Tower Research Capital LLC (TRC) | 221 | New | 0.00% | $0 M | Nov 16, 2026 |
| 29 | Barclays PLC | 214 | -90 (-29.61%) | 0.00% | $0 M | Nov 6, 2026 |
| 30 | BNP Paribas Financial Markets | 46 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 31 | KERR FINANCIAL PLANNING Corp | 24 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 32 | Osaic Holdings, Inc. | 10 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 33 | Rockefeller Capital Management L.P. | 8 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 34 | Citigroup Inc | 1 | -96 (-98.97%) | 0.00% | $0 M | Nov 4, 2026 |
| 35 | IFP Advisors, Inc | 1 | New | 0.00% | $0 M | Oct 16, 2026 |
Mutual funds holding Atara Biotherapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 158,646 | $2 M | 1.6% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 82,758 | $1 M | 0.81% | <0.01% | +47% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 29,408 | $0 M | 0.29% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 17,227 | $0 M | 0.17% | 0.01% | +65% | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 16,238 | $0 M | 0.16% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 14,000 | $0 M | 0.14% | 0.11% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 10,479 | $0 M | 0.10% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 8,665 | $0 M | 0.09% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 4,612 | $0 M | 0.05% | <0.01% | +72% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 2,844 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 2,799 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 1,643 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,147 | $0 M | 0.01% | <0.01% | +48% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 210 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 135 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 15 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Atara Biotherapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | AnhCo NguyenPresident and CEO, Director | Sell | -6,094 | $6.460 | $39 K | 126,681 | Form 4 |
| filed | Brian N. CherryDirector | Buy | +104,166 | $9.600 | $1000 K | 166,486 | Form 4 |
| filed | AnhCo NguyenPresident and CEO, Director | Sell | -5,062 | $8.080 | $41 K | 132,775 | Form 4 |
| filed | Redmile Group, LLCDirector | Option exerciseindirect | +195,211 | — | — | 636,912 | Form 4 |
| filed | Redmile Group, LLCDirector | Shares withheld for taxindirect | -60 | — | — | 636,852 | Form 4 |
| filed | Brian N. CherryDirector | Grant or award | +24,000 | — | — | 62,320 | Form 4 |
| filed | Matthew K. FustDirector | Grant or award | +12,000 | — | — | 30,188 | Form 4 |
| filed | Gregory Austin CiongoliDirector, 10% owner | Grant or award | +12,000 | — | — | 12,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Atara Biotherapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-1.3 reverse split
Trading halts
- 2026-05-07 19:30 UTC, code LUDP, resumed 19:40 UTC
- 2026-05-07 16:14 UTC, code LUDP, resumed 16:19 UTC
- 2026-05-07 14:50 UTC, code LUDP, resumed 14:55 UTC
- 2025-01-16 13:25 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 114 shares at $9.43
- : 2,836 shares at $9.31
- : 1,707 shares at $9.38
- : 216 shares at $9.37
- : 283 shares at $9.40
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Atara Biotherapeutics, Inc. scorecard#
Passes 11 of the 18 checks that could be worked out: strongest in growth (4 of 5), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 23, 2026.
Valuation3 of 5
- ✓P/E below its peers' median2.9×P/E 2.9× against Biotechnology's median of 17.5×.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median0.8×Price to sales 0.8× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-53.0%Free cash flow is -53.0% of the market value.
- ✓Earnings yield above the 10-year Treasury yield34.0%Earnings yield 34.0% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 5
- ✗Revenue grew in the newest year-6.3%Revenue down 6.3% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years23.9%23.9% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median23.9%23.9% a year against Biotechnology's median of 12.9% (181 companies).
- ✓Earnings per share grew in the newest year2.57 vs -11.41Diluted EPS 2.57 in fiscal 2025 against -11.41 the year before (report's currency).
- ✓Net income higher than five years earlier$33 M$33 M in fiscal 2025 against -$307 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability3 of 4
- ✓Profitable in the newest year$33 MNet income $33 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median29.7%29.7% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier29.7%29.7% in fiscal 2025 against -441.3% in 2022.
Financial health1 of 3
- ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.82 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✓Operating income covers interest five times9.5×Operating income 9.5 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year69.8%Diluted shares up 69.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Atara Biotherapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 29.7% | -60.5% | |
| Net margin | 27.1% | -68.9% | |
| Revenue growth, 3 years a year | 23.9% | 12.9% | |
| Revenue growth | -6.3% | 15.8% | |
| Free cash flow margin | -42.2% | -61.5% |
4of 7on the Piotroski tests of financial strength
- Revenue fell 6.3% against the year before.
- Free cash flow was negative: -$51 million.
- Only -156% of net income arrived as cash from operations.
- The share count rose 69.8% in the year.
Atara Biotherapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 121−6.3%100% | 129+1404%100% | 8.6−86.5%100% | 64—100% | — | — | — | — | — | — | |
| Research and development | 37−75.3%31.0% | 151−32.6%117% | 225−17.5%2622% | 273−3.4%429% | 282+15.3%— | 245+13.2%— | 216+29.0%— | 167+106%— | 81+43.7%— | 57—— | |
| General and administrative | 26−34.2%21.7% | 40−21.7%30.9% | 51−28.9%594% | 72−9.2%113% | 79+22.4%— | 64−19.1%— | 80+14.3%— | 70+72.7%— | 40+63.1%— | 25—— | |
| Operating expenses | — | — | — | 344−4.6%541% | 361+16.7%— | 309+4.5%— | 296+24.7%— | 237+95.1%— | 122+49.6%— | 81—— | |
| Total costs and expenses | 85−60.0%70.3% | 212−25.4%165% | 285−17.3%3319% | 344—541% | — | — | — | — | — | — | |
| Operating income | 36—29.7% | −83—−64.7% | −276—−3219% | −281—−441% | −340—— | −309—— | −296—— | −237—— | −122—— | −81—— | |
| Interest expense and finance costs | 3.8−17.8%3.1% | 4.6−12.7%3.6% | 5.3+1317%61.6% | 0.4—0.6% | — | — | — | — | — | — | |
| Other non-operating income (expense) | −0.0−106%−0.0% | 0.5—0.4% | −0.2—−2.9% | −0.7r2.0−291%−1.1% | 0.4−85.0%— | 2.4−48.1%— | 4.7−25.9%— | 6.4+214%— | 2.0−8.0%— | 2.2—— | |
| Income before tax | 33—27.1% | −85—−66.2% | −276—−3221% | −228—−359% | −340—— | −307—— | −291—— | −231—— | −120—— | −79—— | |
| Income tax | 0.0—0.0% | −0.0−180%−0.0% | 0.0+25.0%0.2% | 0.0−73.9%0.0% | 0.0+207%— | 0.0+25.0%— | 0.0—— | −0.0—— | −0.0−240%— | 0.0—— | |
| Net income including minority interests | 33—27.1% | −85—−66.2% | −276—−3221% | −228—−359% | −340—— | −307—— | −291—— | −231—— | −119—— | −79—— | |
| Net income attributable to shareholders | 33—27.1% | −85—−66.2% | −276—−3221% | −228—−359% | −340—— | −307—— | −291—— | −231—— | −119—— | −79—— | |
| Earnings per share, basic | 2.61—— | -11.41—— | -65.19r-2.61—— | -2.24—— | -3.63—— | -4.15—— | -5.67—— | -5.27—— | -4.00—— | -2.75—— | |
| Earnings per share, diluted | 2.57—— | -11.41—— | -65.19r-2.61—— | -2.24—— | -3.63—— | -4.15—— | -5.67—— | -5.27—— | -4.00—— | -2.75—— | |
| Shares, weighted average (basic) | 13+67.5%— | 7.5+76.8%— | 4.2r106−95.8%— | 102+8.9%— | 94+26.6%— | 74—— | — | — | — | — | |
| Shares, weighted average (diluted) | 13+69.8%— | 7.5+76.8%— | 4.2r106−95.8%— | 102+8.9%— | 94+26.6%— | 74+44.2%— | 51+17.1%— | 44+46.7%— | 30+3.9%— | 29—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 8.5−66.1%41.9% | 25−3.1%22.9% | 26−72.2%15.6% | 93−12.4%24.7% | 106−47.1%22.7% | 200+170%34.1% | 74+22.4%21.7% | 61−23.4%15.5% | 79+65.2%36.4% | 48—18.2% | |
| Short-term investments | 0−100%0.0% | 17−32.5%16.0% | 26−82.7%15.6% | 150−43.4%39.8% | 265−11.7%56.6% | 300+62.5%51.1% | 185−25.8%53.9% | 249+187%63.5% | 87−58.2%39.9% | 208—78.7% | |
| Receivables | 1.3−15.5%6.2% | 1.5−95.7%1.4% | 34−15.2%20.6% | 40+3979%10.7% | 1.0−21.1%0.2% | 1.3—0.2% | 0—0.0% | — | — | — | |
| Inventory | 0−100%0.0% | 11+9.8%9.8% | 9.7+512%5.9% | 1.6—0.4% | 0—0.0% | — | — | — | — | — | |
| Other current assets | 2.5−75.5%12.2% | 10+63.6%9.3% | 6.2−40.0%3.7% | 10−16.7%2.7% | 12−41.6%2.6% | 21+54.6%3.6% | 14+17.4%4.0% | 12+97.7%3.0% | 5.9+26.1%2.7% | 4.7—1.8% | |
| Current assets | 12−81.2%60.4% | 65−36.3%59.5% | 102−65.5%61.6% | 295−23.3%78.4% | 385−26.5%82.2% | 523+91.7%89.0% | 273−15.1%79.6% | 321+86.7%82.0% | 172−33.9%79.1% | 261—98.7% | |
| Property, plant and equipment | 0.1−94.4%0.4% | 1.3−66.4%1.2% | 3.9−38.8%2.3% | 6.3−88.3%1.7% | 54+6.5%11.5% | 51−6.8%8.6% | 54−21.0%15.8% | 69+55.4%17.5% | 44+1254%20.3% | 3.3—1.2% | |
| Right-of-use (leased) assets | 7.1−82.3%34.9% | 40−27.5%36.5% | 55−19.2%33.2% | 68+160%18.1% | 26+113%5.6% | 12−12.2%2.1% | 14—4.1% | 0—0.0% | — | — | |
| Total assets | 20−81.5%100% | 109−34.1%100% | 166−56.0%100% | 376−19.6%100% | 468−20.4%100% | 588+71.5%100% | 343−12.5%100% | 392+79.9%100% | 218−17.5%100% | 264—100% | |
| Accounts payable | 0.1−97.1%0.6% | 4.4+18.5%4.0% | 3.7−46.4%2.2% | 6.9−60.4%1.8% | 17+144%3.7% | 7.1−10.6%1.2% | 8.0+114%2.3% | 3.7−74.7%0.9% | 15+430%6.8% | 2.8—1.1% | |
| Current liabilities | 15−88.9%73.7% | 135−5.4%123% | 142+80.2%85.9% | 79−25.4%21.0% | 106+27.6%22.6% | 83+126%14.1% | 37−8.1%10.7% | 40+44.6%10.2% | 28+186%12.7% | 9.7—3.7% | |
| Lease liabilities (non-current) | 9.3−68.8%46.2% | 30−34.5%27.4% | 46−21.3%27.6% | 58+128%15.4% | 26+95.7%5.5% | 13−7.7%2.2% | 14—4.1% | 0—0.0% | — | — | |
| Non-current liabilities | — | — | — | — | — | — | — | 13+6.0%3.3% | 12+2339%5.6% | 0.5—0.2% | |
| Total liabilities | 59−71.5%290% | 206−22.0%189% | 265+6.0%160% | 250+32.5%66.4% | 189+49.9%40.3% | 126+141%21.4% | 52−1.5%15.2% | 53+32.7%13.5% | 40+292%18.3% | 10—3.9% | |
| Retained earnings | −2,022—−9992% | −2,055—−1883% | −1,969—−1190% | −1,693—−450% | −1,465—−313% | −1,125—−191% | −818—−239% | −527—−135% | −297—−136% | −177—−67.1% | |
| Shareholders' equity | −39—−190% | −97−198%−89.2% | 99r−99−21.6%60.0% | 127−54.7%33.6% | 280−39.5%59.7% | 462+59.0%78.6% | 291−14.3%84.8% | 339r339+90.7%86.6% | 178−29.9%81.7% | 254—96.1% | |
| Total liabilities and equity | 20−81.5%100% | 109−34.1%100% | 166−56.0%100% | 376−19.6%100% | 468−20.4%100% | 588+71.5%100% | 343−12.5%100% | 392+79.9%100% | 218−17.5%100% | 264—100% | |
| Shares outstanding | 7.3+25.0%— | 5.9+37.6%— | 4.3r106−95.6%— | 96+4.6%— | 92+10.0%— | 83+46.8%— | 57+23.6%— | 46+49.5%— | 31+6.2%— | 29r29—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 2.1−58.1%1.8% | 5.1+4.6%3.9% | 4.8−14.6%56.3% | 5.7−39.5%8.9% | 9.3+12.2%— | 8.3+17.9%— | 7.1+89.4%— | 3.7+290%— | 1.0+150%— | 0.4—— | |
| Share-based compensation | 9.8−63.9%8.1% | 27−40.5%20.9% | 45−15.7%529% | 54−0.1%84.7% | 54+4.9%— | 51−0.7%— | 52+52.9%— | 34+46.4%— | 23+37.6%— | 17—— | |
| Cash from operating activities | −51—−42.2% | −69—−53.3% | −193—−2251% | −270—−425% | −221—— | −181—— | −236—— | −180—— | −88—— | −60—— | |
| Capital expenditure | 0—0.0% | −0.2—−0.2% | −1.2—−14.3% | −4.2—−6.6% | −11—— | −4.5—— | −5.7—— | −36—— | −20—— | −3.0—— | |
| Cash from investing activities | 18+110%15.0% | 8.6−93.0%6.7% | 124−39.0%1445% | 203+812%319% | 22—— | −121−300%— | 60—— | −196−296%— | 100r99+19.3%— | 84—— | |
| Shares issued | 1.5−84.3%1.2% | 9.3+338%7.2% | 2.1−90.2%24.9% | 22−77.8%34.4% | 99+42.6%— | 69+45.0%— | 48+0.3%— | 48+148%— | 19—— | 0—— | |
| Cash from financing activities | 16−72.8%13.3% | 59+2849%46.0% | 2.0−96.2%23.4% | 53−48.9%83.5% | 104−75.7%— | 428+126%— | 189−47.2%— | 358+1683%— | 20+3862%— | 0.5—— | |
| Change in cash | — | — | — | — | — | — | — | — | 31+29.0%— | 24—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 4.0−97.4%100% | 1.2−64.6%100% | 0.6−96.4%100% | 0.5−99.5%100% | 1.6*−95.1%100% | 3.5−91.4%100% | 18−38.6%100% | 98+259%100% | 33*+670%100% | 40—100% | 29—100% | 27—100% | 4.3*—100% | |
| Cost of revenue | — | 0.3+130%21.7% | — | — | — | 0.1—3.3% | — | — | — | — | — | — | — | |
| Research and development | — | 1.1−62.4%89.8% | 1.3−81.6%213% | 0.2−99.4%31.8% | — | 2.9−93.3%84.7% | 7.3−78.1%41.6% | 27−39.7%28.0% | 29*−42.1%87.7% | 44—109% | 33—116% | 46—166% | 50*—1167% | |
| General and administrative | 15−53.8%366% | 2.8−29.0%231% | 3.8−41.4%605% | 3.6−68.7%697% | 4.3*−54.7%268% | 4.0−61.7%115% | 6.5−26.9%37.1% | 11+3.3%11.7% | 9.4*−17.6%28.8% | 10—25.9% | 8.9—31.1% | 11—40.6% | 11*—269% | |
| Total costs and expenses | 18−86.0%444% | 4.2−40.3%343% | 5.4−62.8%849% | 3.9−93.5%753% | 4.2*−90.8%261% | 7.0−88.7%204% | 14−69.3%81.8% | 59+1.3%60.5% | 45*−30.0%137% | 62—154% | 47—164% | 59—214% | 64*—1510% | |
| Operating income | −14−152%−344% | −3.0—−243% | −4.7−248%−749% | −3.4−109%−653% | −2.6*—−161% | −3.6—−104% | 3.2—18.2% | 39—39.5% | −12*—−37.3% | −22—−54.1% | −18—−63.7% | −31—−114% | −60*—−1410% | |
| Interest and finance income | — | 0.1−66.7%5.6% | — | — | — | 0.2—5.9% | — | — | — | — | — | — | — | |
| Interest expense and finance costs | — | — | 0.2−80.3%30.3% | 0.8−18.4%161% | 0.9*−12.1%56.1% | 0.9−23.2%26.3% | 1.0−23.0%5.5% | 1.0−11.8%1.0% | 1.0*−13.5%3.1% | 1.2—2.9% | 1.3—4.4% | 1.2—4.2% | 1.2*—27.7% | |
| Other non-operating income (expense) | 0.8—21.3% | 0.7—60.5% | 0−100%0.0% | 0—0.0% | 0.1r−0.0*—6.5% | −0.7r0.0−226%−20.3% | 0.0—0.1% | −0.0−116%−0.0% | −0.1*—−0.3% | 0.6—1.4% | −0.0—−0.0% | 0.1—0.2% | −0.0*—−0.3% | |
| Income before tax | −15−162%−369% | −2.2—−182% | −4.8−302%−767% | −4.1−111%−803% | −3.4*—−214% | −4.3—−124% | 2.4—13.6% | 38—38.7% | −13*—−38.8% | −22—−54.6% | −19—−66.5% | −32—−116% | −60*—−1421% | |
| Income tax | 0.0−91.7%0.0% | 0*−100%0.0% | 0.0−66.7%0.2% | 0—0.0% | 0*—0.0% | 0.0—0.8% | 0.0—0.0% | 0−100%0.0% | −0.0*−273%−0.1% | −0.0—−0.0% | 0—0.0% | 0.0—0.1% | 0.0*—0.3% | |
| Net income including minority interests | −15−162%−369% | −2.2*—−182% | −4.8−303%−767% | −4.1−111%−803% | −3.4*—−214% | −4.3—−125% | 2.4—13.6% | 38—38.7% | −13*—−38.8% | −22—−54.5% | −19—−66.5% | −32—−116% | −60*—−1422% | |
| Net income attributable to shareholders | −15−162%−369% | −2.2—−182% | −4.8−303%−767% | −4.1−111%−803% | −3.4*—−214% | −4.3—−125% | 2.4—13.6% | 38—38.7% | −13*—−38.8% | −22—−54.5% | −19—−66.5% | −32—−116% | −60*—−1422% | |
| Earnings per share, basic | — | -0.15—— | -0.32−260%— | -0.29−108%— | — | -0.32—— | 0.20—— | 3.53—— | — | -2.93—— | -3.10—— | -5.65r-0.23—— | — | |
| Earnings per share, diluted | — | -0.15—— | -0.32−268%— | -0.29−108%— | — | -0.32—— | 0.19—— | 3.50—— | — | -2.93—— | -3.10—— | -5.65r-0.23—— | — | |
| Shares, weighted average (basic) | 15+13.0%— | 15+13.0%— | 15+23.3%— | 14+30.8%— | — | 14+81.7%— | 12+98.6%— | 11+91.4%— | — | 7.5—— | 6.1—— | 5.6r141—— | — | |
| Shares, weighted average (diluted) | 15+13.0%— | 15+13.0%— | 15+22.1%— | 14+29.8%— | — | 14+81.7%— | 12+100%— | 11+93.0%— | — | 7.5—— | 6.1—— | 5.6r141—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.1—21.8% | 4.1−29.4%21.8% | 3.2−80.9%15.3% | 8.4−39.6%41.8% | 8.5−66.1%41.9% | 5.7−87.6%19.0% | 17−46.0%45.8% | 14−60.6%22.3% | 25−3.1%22.9% | 46—32.6% | 31—26.7% | 35—21.2% | 26—15.6% | |
| Short-term investments | 5.9—31.5% | 5.9−26.4%31.5% | 6.7+22.7%31.6% | — | 0−100%0.0% | 8.0−61.6%26.4% | 5.4+36.2%14.7% | 0−100%0.0% | 17−32.5%16.0% | 21—14.5% | 4.0—3.4% | 11—6.7% | 26—15.6% | |
| Receivables | 0.7—3.7% | 0.7−63.9%3.7% | 0.3—1.5% | 0−100%0.0% | 1.3−15.5%6.2% | 1.9+43.3%6.3% | 0−100%0.0% | 8.9−75.2%14.3% | 1.5−95.7%1.4% | 1.3—0.9% | 2.4—2.1% | 36—21.7% | 34—20.6% | |
| Inventory | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 11+9.8%9.8% | 14—9.8% | 19—16.0% | 16—9.7% | 9.7—5.9% | |
| Other current assets | 0.7—3.8% | 0.7−74.9%3.8% | 3.3+36.3%15.9% | 3.8−11.7%19.1% | 2.5−75.5%12.2% | 2.8−69.5%9.3% | 2.4−57.8%6.6% | 4.3−46.9%7.0% | 10+63.6%9.3% | 9.2—6.5% | 5.8—4.9% | 8.1—4.9% | 6.2—3.7% | |
| Current assets | 11—60.8% | 11−38.6%60.8% | 14−45.4%64.4% | 12−55.2%60.9% | 12−81.2%60.4% | 18−79.9%61.1% | 25−60.3%67.1% | 27−74.5%43.8% | 65−36.3%59.5% | 92—64.4% | 62—53.2% | 106—64.4% | 102—61.6% | |
| Property, plant and equipment | 0.0—0.2% | 0.0−74.1%0.2% | 0.0−76.7%0.2% | 0.1−80.7%0.3% | 0.1−94.4%0.4% | 0.1−91.1%0.5% | 0.2−92.4%0.5% | 0.3−90.5%0.5% | 1.3−66.4%1.2% | 1.7—1.2% | 2.3—2.0% | 3.0—1.8% | 3.9—2.3% | |
| Right-of-use (leased) assets | 6.5—34.9% | 6.5−39.3%34.9% | 6.7−39.3%31.8% | 6.9−78.3%34.4% | 7.1−82.3%34.9% | 11−76.6%35.5% | 11−77.5%29.9% | 32−39.0%51.1% | 40−27.5%36.5% | 46—32.1% | 49—41.7% | 52—31.5% | 55—33.2% | |
| Total assets | 19—100% | 19−38.3%100% | 21−43.0%100% | 20−67.8%100% | 20−81.5%100% | 30−78.9%100% | 37−68.5%100% | 62−62.5%100% | 109−34.1%100% | 143—100% | 117—100% | 165—100% | 166—100% | |
| Accounts payable | 0.8—4.1% | 0.8+140%4.1% | 0.8−53.2%3.9% | 0.6−54.0%3.2% | 0.1−97.1%0.6% | 0.3−85.2%1.1% | 1.8−66.5%4.8% | 1.4−51.5%2.2% | 4.4+18.5%4.0% | 2.1—1.5% | 5.3—4.5% | 2.9—1.7% | 3.7—2.2% | |
| Current liabilities | 6.6—35.3% | 6.6−63.6%35.3% | 6.8−53.0%32.6% | 5.6−88.2%28.2% | 15−88.9%73.7% | 18−88.4%59.9% | 15−90.2%39.5% | 48−73.5%77.2% | 135−5.4%123% | 156—109% | 148—126% | 181—109% | 142—85.9% | |
| Lease liabilities (non-current) | 8.5—45.6% | 8.5−43.5%45.6% | 8.8−43.1%41.8% | 9.1−66.0%45.4% | 9.3−68.8%46.2% | 15−57.4%49.7% | 15−60.1%41.8% | 27−36.7%43.1% | 30−34.5%27.4% | 35—24.7% | 39—33.0% | 42—25.5% | 46—27.6% | |
| Total liabilities | 57—304% | 57−15.4%304% | 58−19.4%276% | 57−51.1%287% | 59−71.5%290% | 67−71.4%221% | 72−68.5%195% | 117−55.6%189% | 206−22.0%189% | 233—163% | 228—195% | 264—159% | 265—160% | |
| Retained earnings | −2,033—−10926% | −2,033—−10926% | −2,031—−9660% | −2,026—−10132% | −2,022—−9992% | −2,018—−6691% | −2,014—−5458% | −2,017—−3250% | −2,055—−1883% | −2,042—−1431% | −2,020—−1722% | −2,001—−1211% | −1,969—−1190% | |
| Shareholders' equity | −38—−204% | −38—−204% | −37—−176% | −37—−187% | −39—−190% | −37—−121% | −35—−95.0% | −55—−88.8% | −97−198%−89.2% | −91—−63.4% | −111—−94.5% | −98—−59.5% | 99r−99—60.0% | |
| Total liabilities and equity | 19—100% | 19−38.3%100% | 21−43.0%100% | 20−67.8%100% | 20−81.5%100% | 30−78.9%100% | 37−68.5%100% | 62−62.5%100% | 109−34.1%100% | 143—100% | 117—100% | 165—100% | 166—100% | |
| Shares outstanding | 10—— | 10+41.3%— | 9.4+35.3%— | 8.5+43.7%— | 7.3+25.0%— | 7.2+25.6%— | 7.0+42.3%— | 5.9−95.1%— | 5.9+37.6%— | 5.7—— | 4.9—— | 120—— | 4.3r106—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−97.0%2.4% | 0.0*−91.7%0.2% | 0.0*−94.1%2.2% | 0.0−98.4%5.6% | 0.0*−95.5%3.1% | 0.0*−97.1%1.0% | 0.2*−82.3%1.3% | 1.8+29.0%1.8% | 1.1*−8.7%3.4% | 1.2*—3.1% | 1.3*—4.6% | 1.4—5.1% | 1.2*—28.3% | |
| Share-based compensation | 3.1−77.9%78.6% | 0.5−62.7%37.3% | 0.4−85.9%62.5% | 0.7−82.2%145% | 1.5*−74.1%95.1% | 1.2−80.9%35.5% | 2.8−55.8%15.9% | 4.2−49.9%4.3% | 5.8*−41.1%17.8% | 6.4—16.0% | 6.3—22.1% | 8.4—30.7% | 9.9*—233% | |
| Cash from operating activities | −13—−328% | −0.9*—−71.8% | −3.3*—−530% | −3.1—−596% | −5.7*—−357% | −9.8*—−283% | −7.3*—−41.6% | −28—−28.7% | −24*—−74.7% | −4.0*—−9.9% | −11*—−37.2% | −30—−108% | −50*—−1185% | |
| Capital expenditure | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | −0.1*—−0.3% | 0*—0.0% | −0.0*—−0.1% | −0.1—−0.5% | −0.0*—−1.0% | |
| Cash from investing activities | 2.6−79.8%66.8% | 0.8*—68.1% | −6.6*—−1052% | 0−100%0.0% | 8.4*+150%529% | −2.4*—−70.1% | −5.1*−170%−28.8% | 17+16.9%17.5% | 3.4*−66.0%10.3% | −17*—−41.5% | 7.2*—25.1% | 15—53.8% | 9.9*—234% | |
| Shares issued | 8.6+477%218% | 0.9*−41.2%71.9% | 4.8*—766% | 3.0—572% | −0.0*—−1.6% | 1.5*—43.3% | 0*—0.0% | 0−100%0.0% | 0*−100%0.0% | 0*—0.0% | −0.0*—−0.1% | 9.4—34.3% | 1.5*—36.4% | |
| Cash from financing activities | 8.7−45.1%218% | 0.9*−16.0%71.9% | 4.8*−68.5%766% | 3.0—572% | −0.0*—−0.2% | 1.0*−97.1%30.3% | 15*—87.1% | −0.3−101%−0.3% | −0.3*−122%−1.0% | 36*—89.1% | −0.3*—−1.1% | 24—88.2% | 1.5*—35.6% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Atara Biotherapeutics, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters2 offices | — |
| 🇮🇪 Ireland | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Atara Biotherapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Nguyen | $1.1 M | $1.1 M | $1.0 M | $22 |
| 2024AnhCo Nguyen | $1.7 M | $1.3 M | $872 K | $3 |
| 2023Dr. Touchon served | $4.4 M | $557 K | $2.3 M | $3 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Atara Biotherapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Restructuring 4 · Directors and officers 5 · Material agreement 3 · Unregistered share sale 1 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officersResults announced | 8-K | |
| Restructuring | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Restructuring | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Lobbying by Atara Biotherapeutics, Inc.#
$30 K spent on lobbying the US Congress and federal agencies in 2025.
Lobbying firms hired in 2025
King & Spalding LLP $30 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $20 K | — | 2 |
| 2025 | $30 K | — | 2 |
| 2024 | $120 K | — | 4 |
| 2023 | $240 K | — | 4 |
| 2022 | $240 K | — | 4 |
| 2021 | $220 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Atara Biotherapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Atara Biotherapeutics, Inc.#
2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $97 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate ScientistMicrobiologists | 1 | $73 K |
| Sr. Data Engineer, Process MonitoringIndustrial Engineers | 1 | $120 K |
Where: Thousand Oaks, CA 1 · Frisco, TX 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 2 | 2 | $97 K | 2 |
| FY2024 | 2 | 2 | $87 K | 2 |
| FY2023 | 13 | 13 | $101 K | 13 |
| FY2022 | 8 | 8 | $115 K | 8 |
| FY2021 | 14 | 14 | $90 K | 14 |
| FY2020 | 8 | 8 | $110 K | 8 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Atara Biotherapeutics, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | 31 | · | · | · | · | · | · | · | · | · | 31 |
| 2024 | 44 | · | · | · | · | · | · | · | · | · | · | · | 44 |
| 2023 | · | · | · | · | · | · | · | · | · | · | 73 | · | 73 |
| 2022 | 140 | · | · | · | · | · | · | 77 | · | · | · | · | 217 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 29% of workforce | Restructuring planSEC 8-K | “(the “Company”) announced a reduction in its workforce that will impact approximately 29% of its current employees, retaining approximately 15 employees essential to executing on t…” | Filing | |
| 30% of workforce | Restructuring planSEC 8-K | “(the “Company”) announced a reduction in its workforce that will impact approximately 30% of its current employees, retaining approximately 23 employees essential to executing on t…” | Filing | |
| effective | 31 people | LayoffWARN notice | Newbury Park, California | Notice list |
| 50% of workforce | Restructuring planSEC 8-K | “On March 3, 2025, the Company announced a reduction in its workforce that will impact approximately 50% of its current employees following the Company’s decision to discontinue all…” | Filing | |
| 50% of workforce | Restructuring planSEC 8-K | “(the “Company”) announced a reduction in its workforce that will impact approximately 50% of its current employees.” | Filing | |
| 25% of workforce | Restructuring planSEC 8-K | “(the “Company”) announced a reduction in its workforce that will impact approximately 25% of its current employees.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Atara Biotherapeutics, Inc. compares in Biotechnology
- Market cap$96 M · higher than 35% of 726
- Revenue$121 M · higher than 71% of 647
- Net margin27.1% · higher than 90% of 408
- Revenue growth-6.3% · higher than 37% of 438
- P/E ratio2.9× · lower than 92% of 100
- Price / sales0.8× · lower than 96% of 339
- FCF yield-53.0% · higher than 22% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Atara Biotherapeutics, Inc.🇺🇸 | $96 M | 2.9× | 27.1% | -6.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 23, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Atara Biotherapeutics, Inc.? Verify and update this profile — free
Show Atara Biotherapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.